Novo Nordisk A/S Common Stock (NVO)
40.69
-0.69 (-1.67%)
NYSE · Last Trade: Nov 10th, 10:35 AM EST
News & Press Releases
Eli Lilly Is Now Worth Nearly 9 Novo Nordisks. Here's How the Gap Got So Wide.fool.com
The companies are competing in the weight loss drug market.
Via The Motley Fool · November 9, 2026
Novo Nordisk's Wegovy Pill Has Topped 5 Million Prescriptions. Is the Stock a Buy Now?fool.com
Novo Nordisk is looking to build a volume-driven business, but the successful launch of the Wegovy pill is just the first step.
Via The Motley Fool · November 8, 2026
What Novo Nordisk A/S (NVO) Said on Its Q3 Earnings Callmarketbeat.com
Novo Nordisk A/S (NYSE:NVO) raised its 2026 sales and profit outlook after third-quarter adjusted sales rose 4% to DKK 79.2 billion, supported by demand for its obesity treatments and expanding use of the Wegovy pill.
The company now expects adjusted sales growth and adjusted operating profit growt
Via MarketBeat · November 8, 2026
Novo Nordisk Just Delivered Great News for Investors. Is a Comeback Finally Underway?fool.com
Novo got a much-needed boost from its latest earnings report.
Via The Motley Fool · November 7, 2026
Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trialsfool.com
Everyone is talking about the GLP-1 battle between Eli Lilly and Novo Nordisk, but Pfizer wants in on the fight, too.
Via The Motley Fool · November 7, 2026
2 Growth Stocks to Buy in November Without Any Hesitationfool.com
They have both outperformed the broader equity market over the long run.
Via The Motley Fool · November 5, 2026
Novo Nordisk: 3 Key Takeaways for Long-Term Investorsfool.com
U.S. pricing pressure weighs on Novo Nordisk's growth, but management is counting on the pipeline to offset it over the long haul.
Via The Motley Fool · November 4, 2026
Novo Nordisk (NVO) Q3 2026 Earnings Call Transcriptfool.com
Wegovy pill uptake and CagriSema trial results shape the growth recovery story.
Via The Motley Fool · November 4, 2026
Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.fool.com
Viking aims to enter the weight loss drug market.
Via The Motley Fool · November 4, 2026
3 Dirt Cheap Dividend Stocks to Buy in November 2026fool.com
These high-yielding stocks pay up to 7.4% in dividends.
Via The Motley Fool · November 3, 2026
Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 Billion
Growing Demand for Next-Generation Therapies Is Putting Peptide Innovation at the Center of Healthcare's Biggest Growth Markets
By FN Media · Via GlobeNewswire · November 3, 2026
Peptide Therapies Are Changing the Future of Medicine — And the Market Could Reach $335 Billion
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(OTCQX:RHHBY),(NYSE:NVO),(NASDAQ:VKTX),(NYSE:LLY) EQNX::TICKER_END
Via FinancialNewsMedia · November 3, 2026
GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?marketbeat.com
Compares the Roundhill GLP-1 & Weight Loss ETF (OZEM) and the newer REX Peptide ETF (PEPT), examining holdings, fees, and overlap as GLP-1 drug demand from Eli Lilly and Novo Nordisk continues to grow.
Via MarketBeat · November 2, 2026
Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugsfool.com
The market for GLP-1 drugs is forecast to explode. It may be understated still.
Via The Motley Fool · November 2, 2026
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.fool.com
Trial results for its weight loss drugs could justify a higher valuation for the clinical-stage biotech.
Via The Motley Fool · November 2, 2026
Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?fool.com
Novo Nordisk is shifting its business model, with 2026 likely to represent an inflection point.
Via The Motley Fool · November 1, 2026
Novo Has Big Plans for 2030. Should You Buy the Stock Now?fool.com
The company’s comeback strategy looks sound.
Via The Motley Fool · October 29, 2026
The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth
Breakthroughs in obesity, diabetes, oncology, and targeted therapies are driving fresh interest in peptide-based medicines and the companies developing the next generation of treatments.
By FN Media · Via GlobeNewswire · October 29, 2026
The $294 Billion Peptide Boom: Biotech Companies Positioned for the Next Wave of Growth
EQNX::TICKER_START (OTCQB:PNGAF),(CSE:BPC),(NYSE:NVO),(NYSE:HIMS),(NYSE:ENHA),(NYSE:LLY) EQNX::TICKER_END
Via FinancialNewsMedia · October 29, 2026
Amgen vs. Novo Nordisk: Which Healthcare Giant's Stock Is a Better Buy in 2026?fool.com
Amgen's 9.9% revenue growth outpaces Novo Nordisk, but a 33.1% net margin and lower valuation multiples tell a different profitability story.
Via The Motley Fool · October 27, 2026
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalystsmarketbeat.com
MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment.
Via MarketBeat · October 26, 2026
Bristol Myers Squibb vs. Novo Nordisk: Stable Scale vs. GLP-1 Volatilityfool.com
Bristol Myers Squibb has led in seven of eight quarters, but Novo Nordisk's recent spike signals a shift worth watching for income-focused investors.
Via The Motley Fool · October 22, 2026
Where Will Novo Stock Be in 10 Years?fool.com
The company may lean on its core therapeutic area to help it overcome recent headwinds.
Via The Motley Fool · October 21, 2026
Novo's CagriSema Delivered 25% Weight Loss in Women. Could It Help Turn Around the Beaten-Down Stock?fool.com
Its leading investigational drug demonstrated relatively high levels of weight loss in a late-stage clinical trial.
Via The Motley Fool · October 21, 2026
Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter.fool.com
Viking Therapeutics raised $575 million to fund major obesity drug trials, develop its pipeline, and support commercial development of any approvals for VK2735.
Via The Motley Fool · October 18, 2026